Neogen Corporation filed an 8-K on November 4, 2026, disclosing updated timing on the regulatory review of its previously announced agreement to sell its global Genomics business to Zoetis Inc.

Key Highlights

  • Definitive agreement announced March 2, 2026: Neogen entered into an agreement to sell its global Genomics business to Zoetis Inc.
  • Regulatory reviews ongoing: Both the Australian Competition and Consumer Commission (ACCC) and the New Zealand Commerce Commission (NZCC) are conducting reviews of the transaction.
  • Zoetis divestiture offer: Zoetis has recently offered to divest certain assets in Australia to assist the regulatory clearance process.
  • Expected timeline extended: Neogen disclosed it expects regulatory review to conclude in early 2027.
  • Transaction conditions: Closing remains subject to customary closing conditions and regulatory approvals, according to the filing.

Neogen Updates Regulatory Status of Genomics Sale to Zoetis

Neogen Corporation (NASDAQ:NEOG) filed a current report under Item 8.01 (Other Events) on November 4, 2026, providing an update on the pending sale of its global Genomics business to Zoetis Inc. According to the filing, the definitive agreement for this transaction was originally announced on March 2, 2026, and remains subject to customary closing conditions and regulatory approvals.

The filing indicates that both parties "continue to cooperate" with the ACCC and the NZCC in their ongoing reviews of the transaction. As a development in the regulatory process, the filing states that Zoetis has recently offered to divest certain assets in Australia. Neogen noted that this offer was made to assist the regulatory clearance process.

As a result of these ongoing regulatory proceedings, Neogen disclosed that it now expects the regulatory review to conclude in early 2027. The filing was signed by R. Bryan Riggsbee, Chief Financial Officer of Neogen Corporation, on behalf of the registrant. No financial terms of the transaction were disclosed in this particular filing, and no other business items were covered in the 8-K.

What Was Disclosed

Neogen Corporation disclosed a regulatory timing update for its planned Genomics business sale to Zoetis Inc., noting that Zoetis offered to divest certain Australian assets and that regulatory clearance is now expected in early 2027.